Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR125b2-3p mimics are chemically synthesized double-stranded RNA molecules designed to mimic the activity of endogenous miR-125b-2-3p, a microRNA that acts as a putative tumor suppressor. In breast cancer research, particularly in hormone receptor-positive (HR+) and aromatase inhibitor-resistant breast cancer models, miR-125b-2-3p mimics have been shown to inhibit cell proliferation, colony formation, migration, and mammosphere disruption. These mimics function by downregulating the expression of stemness-associated target genes, such as Integrin alpha-6 (ITGA6) and Transcription factor SOX-2 (SOX2). They are primarily utilized as research-use-only laboratory tools to investigate microRNA biology and potential therapeutic pathways in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR125b2-3p mimics.